ERB-Modified Fluoroquinolones: Antibiotic Activity and PK/PD Profiles

464.1 KB of data on novel Efflux Resistance Breaker (ERB)-modified fluoroquinolone antibiotics. The dataset, authored by Mark Laws and shared on figshare in 2026, includes results showing up to a 512-fold reduction in MIC against multidrug-resistant bacteria and favorable pharmacokinetic profiles.

Use Cases

• Modeling structure-activity relationships for ERB-modified fluoroquinolones based on described antibacterial activity.
• Analyzing pharmacokinetic/pharmacodynamic (PK/PD) profiles for lead compounds like KSN-L22 and BL-7.
• Comparing in vitro MIC data against a panel of resistant pathogens including MRSA and Vancomycin-resistant Enterococci.
• Evaluating enzyme inhibition data for DNA gyrase (wild-type and S84L mutant) mentioned in the description.

Strengths

• Includes specific quantitative results such as a 512-fold MIC reduction and IC50 values of ~3.8 μg/mL for DNA gyrase.
• Reports in vivo efficacy data, including a >4-log bacterial load reduction in a murine infection model.
• Describes a focused scope on a novel antibiotic design strategy with clear experimental outcomes.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset's 464.1 KB size suggests a limited scope, likely containing summary results rather than raw high-throughput screening data.

Provenance

Source

figshare

Collection Method

Likely contains experimental results from a research study on antibiotic design.

Freshness

Last updated 2026-05-29 04:48:42; freshness should be verified.